Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002561 | Cerebrovascular Disorders NIH | 0.71 |
| D019462 | Syncope, Vasovagal NIH | 0.71 |
| D013575 | Syncope NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D054144 | Heart Failure, Diastolic NIH | 0.71 |
| D013616 | Tachycardia, Sinus NIH | 0.71 |
| D002546 | Ischemic Attack, Transient NIH | 0.50 |
| D054143 | Heart Failure, Systolic NIH | 0.50 |
| D013610 | Tachycardia NIH | 0.50 |
| D007022 | Hypotension NIH | 0.50 |
| D015673 | Fatigue Syndrome, Chronic NIH | 0.41 |
| D001281 | Atrial Fibrillation NIH | 0.35 |
| D016584 | Panic Disorder NIH | 0.35 |
| D005356 | Fibromyalgia NIH | 0.32 |
| D054058 | Acute Coronary Syndrome NIH | 0.29 |
| D003327 | Coronary Disease NIH | 0.27 |
| D006333 | Heart Failure NIH | 0.20 |
| D006331 | Heart Diseases NIH | 0.19 |
| D009203 | Myocardial Ischemia NIH | 0.16 |
| D013577 | Syndrome NIH | 0.13 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| D011014 | Pneumonia NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011703 | Sinus tachycardia HPO | 0.71 |
| HP:0012668 | Vasovagal syncope HPO | 0.71 |
| HP:0001279 | Syncope HPO | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001649 | Tachycardia HPO | 0.50 |
| HP:0002615 | Hypotension HPO | 0.50 |
| HP:0002326 | Transient ischemic attack HPO | 0.50 |
| HP:0004757 | Paroxysmal atrial fibrillation HPO | 0.35 |
| HP:0001635 | Congestive heart failure HPO | 0.20 |
| HP:0001658 | Myocardial infarction HPO | 0.16 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
This study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result, have significant respiratory distress (PaO2/FiO2 ratio <300 mmHg).
Description: The severity rating will be based on the ordinal scale of clinical status as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment Time: 7 daysThis study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result, have significant respiratory distress (PaO2/FiO2 ratio <300 mmHg).
Description: The severity rating will be based on the ordinal scale of clinical status as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment Time: 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports